Takeaways: Optimi Health’s plan to start a Health Canada‑authorized Phase 3 trial of synthetic MDMA‑assisted therapy for PTSD in 2027 positions the company to potentially become an early mover i...
Takeaways: Grey Matter’s focused ultrasound platform aims to offer a non‑invasive option for people whose depression hasn’t improved with medications or therapy, by precisely stimulating deep brain ci...
Takeaways: Quebec’s listing of PrOKEDI on the RAMQ formulary is a key commercial milestone for Bausch Health, turning a specialized, once‑monthly long‑acting risperidone into a publicl...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
